CD8A and neoplasm: Furthermore, 5T33 not only demonstrated efficacy of immune checkpoint inhibitor (CPI) therapy using antibody to programmed death receptor-1 (PD-1) or its ligand (PDL-1), but also showed that CD8+ T cells in tumor-bearing mice post-ASCT significantly upregulated PD-1 (106, 107).